Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 20,000 Shares of Company Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $109.24, for a total value of $2,184,800.00. Following the sale, the chief technology officer owned 1,000 shares in the company, valued at $109,240. This trade represents a 95.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, October 5th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $108.15, for a total value of $2,163,000.00.
• On Thursday, September 24th, David Tsao sold 3,333 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total value of $416,625.00.
• On Wednesday, September 9th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $98.77, for a total value of $1,975,400.00.
• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total value of $928,600.00.

Billiontoone Trading Up 3.1%

BLLN traded up $3.44 during midday trading on Wednesday, hitting $113.89. The company’s stock had a trading volume of 582,091 shares, compared to its average volume of 469,134. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The firm has a market cap of $5.37 billion and a P/E ratio of 157.79. The firm has a 50-day moving average price of $104.67 and a two-hundred day moving average price of $96.89. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, research analysts anticipate that Billiontoone, Inc. will post 0.80 earnings per share for the current year.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results topped expectations: Revenue was about $123.0 million, above the $115.8 million FactSet estimate. Reported earnings per share also exceeded the $0.16 consensus, although sources cite different actual EPS figures ($0.32 and $0.48). BillionToOne Q3 results and guidance
• Positive Sentiment: Higher 2026 revenue guidance: The company raised its full-year revenue outlook, signaling improved expectations for growth. Company announcement
• Negative Sentiment: Multiple insiders sold shares: The CEO, CTO and an SVP reported sales. The transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but do not eliminate—the bearish signal investors could take from insider selling. Insider transaction reports

Institutional Investors Weigh In On Billiontoone

Several institutional investors have recently bought and sold shares of the business. Wasatch Advisors LP increased its position in shares of Billiontoone by 40.2% in the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after acquiring an additional 148,446 shares in the last quarter. Emerald Advisers LLC raised its stake in shares of Billiontoone by 26.8% in the 1st quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock valued at $18,911,000 after acquiring an additional 50,613 shares during the period. Penn Capital Management Company LLC lifted its holdings in shares of Billiontoone by 2.3% during the 3rd quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock valued at $14,143,000 after acquiring an additional 3,034 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Billiontoone by 11.9% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after acquiring an additional 14,072 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its position in Billiontoone by 26.1% during the 1st quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock worth $7,248,000 after purchasing an additional 19,000 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BLLN shares. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Canaccord Genuity Group assumed coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price target on the stock. JPMorgan Chase & Co. decreased their price target on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. Guggenheim boosted their price objective on shares of Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.25.

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.